GSK is taking over development of an avian influenza vaccine candidate as a bird flu outbreak continues in U.S. dairy cows. Meanwhile, CureVac is restructuring and returning its attention to cancer vaccines, which was the initial focus of the mRNA company.
The post GSK Pays CureVac €400M to Pick Up Clinical-Stage mRNA Vaccines for Infectious Diseases appeared first on MedCity News.
Recent Posts
Categories
Related Articles
Top Hospitals for Pacemaker Implantation Surgery in India: What you need to know?
Pacemaker implantation is a life-saving procedure for people with irregular heart rhythms....
Links
When is a public health problem a crisis? LA has the worst...
Remembering Thomas E. Kurtz
By MIKE MAGEE This has been a challenging week for me, but...
Twin Brothers Launch Seen Health with $22M to Provide Culturally-Focused Care for Seniors
Seen Health emerged from stealth on Monday. The company builds on the...
Leave a comment